Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) EBT (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed EBT for 12 consecutive years, with -$30.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT fell 232.97% year-over-year to -$30.6 million, compared with a TTM value of -$99.7 million through Sep 2025, down 1151.78%, and an annual FY2024 reading of -$35.0 million, down 11.05% over the prior year.
  • EBT was -$30.6 million for Q3 2025 at Avalo Therapeutics, down from -$20.7 million in the prior quarter.
  • Across five years, EBT topped out at $98.5 million in Q2 2024 and bottomed at -$121.3 million in Q1 2024.
  • Average EBT over 5 years is -$13.5 million, with a median of -$13.1 million recorded in 2025.
  • Peak annual rise in EBT hit 1302.91% in 2024, while the deepest fall reached 1119.29% in 2024.
  • Year by year, EBT stood at -$19.1 million in 2021, then surged by 48.8% to -$9.8 million in 2022, then grew by 16.6% to -$8.2 million in 2023, then crashed by 330.78% to -$35.2 million in 2024, then grew by 13.09% to -$30.6 million in 2025.
  • Business Quant data shows EBT for AVTX at -$30.6 million in Q3 2025, -$20.7 million in Q2 2025, and -$13.1 million in Q1 2025.